Ms Heleen Vermandere
As a global health researcher with over 10 years of international experience, Heleen is proficient in collecting qualitative and quantitative data in challenging contexts. She combines health sciences, epidemiology and sociology to study health behaviour and to evaluate the impact of health programmes. She has primarily worked on sexual and reproductive health in sub-Saharan Africa, focusing on family planning and infectious diseases such as HIV/AIDS and cervical cancer. For her doctoral thesis she evaluated the acceptability and uptake of the HPV vaccine in Kenya. Given her strong interest in gender, she has also conducted studies on female genital mutilation and violence against women in Egypt. She coordinates the work of various students and manages the day-to-day operations of a Horizon2020 project on cervical cancer screening.
Publications of Heleen2018 Quality of care in family planning services in rural Mozambique with a focus on long acting reversible contraceptives : a cross-sectional survey
Olivier Degomme, Anna Galle, Heleen Vermandere2018 Knowledge and practices of general practitioners at district hospitals towards cervical cancer prevention in Burundi, 2015 : a cross-sectional study
Heleen Vermandere2018 Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya : a prospective cohort study in a malaria endemic setting
Heleen Vermandere2017 Improving contraceptives supply management by addressing the human factor
Olivier Degomme, Anna Galle, Heleen Vermandere2017 The impact of facility audits, evaluation reports and incentives on motivation and supply management among family planning service providers : an interventional study in two districts in Maputo Province, Mozambique
Olivier Degomme, Anna Galle, Heleen Vermandere2017 Factors associated with HIV testing among men who have sex with men in Western Kenya : a cross-sectional study
Heleen Vermandere2016 Uptake of the human papillomavirus vaccine in Kenya : testing the health belief model through pathway modeling on cohort data
Olivier Degomme, Kristien Michielsen, Heleen Vermandere2016 Introduction of HPV vaccination in Kenya
Heleen Vermandere2016 Introduction of HPV vaccination in Kenya
Heleen Vermandere2015 Implementation of an HPV vaccination program in Eldoret, Kenya: results from a qualitative assessment by key stakeholders
Olivier Degomme, Kristien Michielsen, Heleen Vermandere2014 Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya
Olivier Degomme, Kristien Michielsen, Heleen Vermandere
Projects of Heleen
ELEVATE: EarLy dEtection of cerVical cAncer in hard-to-reach populations of women through portable and point-of-care HPV TEsting
The ELEVATE consortium wants to empower women to screen for their cervical cancer risk in any setting while guaranteeing rapid and easy-to-understand results
Project ongoing Health system research Family planning and contraception
Enhancing motivation of family planning service providers as a lever to avoid stock-outs and increase quality of service
Good progress is being made towards ensuring universal access to family planning (FP) services, mainly through strengthening the supply chains, tackling logistic and financial barriers, training of staff, broadening the choice of methods, and providing information and advocacy. However, sound supply-, counseling- and service provision systems, supported by good manuals and Standard Operating Procedures alone can’t guarantee that stock-outs are completely avoided and that quality of service is sufficient to ensure high user satisfaction of both the services provided and the methods used.
Project closed Cervical cancer and HPV
Cervical cancer prevention in Kenya: Introduction of the HPV vaccines
In Kenya, HPV vaccination is not part of the national immunization scheme. The 2 types of HPV-vaccines are however approved and allowed to use in the country. Dr Hillary Mabeya, National Advisor on Adolescent Vaccination at the Ministry of Health (Kenya), received a grant of 9000 HPV vaccines from the GARDASIL Access Program in order to pilot HPV vaccination. The pilot program started in May 2012 and ended in March 2013. Primary school girls (standard 4 to 9, i.e. approximately 9 to 14 years of age) enrolled in 10 randomly selected public schools were the first target group, but in a second phase the program was opened for young girls from the whole community; 2500 girls of the 3000 girls who received the first dose were fully vaccinated at the end of the program. While vaccination occurred at Moi University Hospital, promotion of the HPV-vaccine was school based: health providers informed teachers who on their turn were asked to inform the girls and parents about the upcoming HPV vaccination opportunity.